

# PROGNOSTIC VALUE OF HCV SEROTYPING IN THE EVALUATION OF INTERFERON THERAPY

## **Thesis**

Submitted in Partial Fulfillment of  
M.D Degree In Clinical and Chemical Pathology

**By**

**Shereen Mohamed Fahim**

## **Supervisors**

Prof. Dr. **AMANI IBRAHIM SALEH**

Professor of Clinical Pathology

Prof. Dr. **MOHAMED ALY MADWAR**

Professor & Head of tropical Medicine

Prof. Dr. **MONA MOHAMED RAFIK**

Professor of Clinical Pathology

Dr. **NAHLA MOHAMED ZAKARIA YOUSEF**

Lecturer of Clinical Pathology


Dr. **HANAA AHMED AMER**

Lecturer of Clinical Pathology

Faculty of Medicine

Ain Shams University

1998











---

## ACKNOWLEDGEMENT

I wish to express my deep appreciation and gratitude to Prof. Dr. **AMANI IBRAHIM SALEH**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, sincere effort and outstanding assistance through every step of this study.

I would like to express special thanks and gratitude to Prof. Dr. **MOHAMED ALY MADWAR**, Professor and Chairman of Tropical Medicine Department, Faculty of Medicine, Ain Shams University, for his supervision, kind help, valuable observation and generous support.

I would like to express my deep thanks and sincere appreciation to Prof. Dr. **MONA MOHAMED RAFIK**, Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her valuable suggestions and continuous encouragement.

I wish to express my deep thanks to Dr. **NAHLA M. ZAKARIA YOUSEF**, Lecturer of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her devotion all the time and effort she sacrificed and valuable friendship she offered me in order to start and complete this work.

I wish to extend my thanks to Dr. **HANAA AHMED AMER**, Lecturer of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her sincere help and effort during this work.

Last, but not least, I would like to send my best regards and thanks to My Family for their help and continuous encouragement.

---

Acknowledgement



---

## ABSTRACT

Hepatitis C virus commonly caused persistent infection and chronicity. HCV infection can lead to serious consequences including cirrhosis and hepatocellular carcinoma.

In this study a trial was done to determine the prevalence of HCV serotype in Egyptian patients with chronic hepatitis C infection and whether serotyping correlates with the genotyping methods. In addition, a trial was done to find out the predictors of response to IFN-alpha therapy in these patients.

This study was done on 51 cases diagnosed as having chronic HCV infection. Detection of HCV RNA was performed by qualitative PCR for all patients before and after treatment by IFN-alpha for 6 months. In addition, HCV RNA quantitation was performed for only 36 patients before treatment. HCV serotyping was performed before treatment for all patients using Murex 1-6 HCV serotyping assay.

This study revealed that serotype 4 is the prevalent serotype in Egypt (74.5%). Most of the responders are of serotype 4. Good correlation exists between both serotyping and genotyping assays. Liver transaminases are not predictors for HCV viremia. Follow up of chronic HCV patients under treatment could be done by HCV RNA.

We conclude that serotyping assays can be used as front-line typing approach in patients with chronic hepatitis C infection.

---

Abstract





---

## LIST OF ABBREVIATIONS

ALT:	Alanine aminotransferase.
AST:	Aspartate aminotransferase.
b.DNA:	Branched deoxyribonucleic acid.
C:	Core.
CAH:	Chronic active hepatitis.
cDNA:	Complementary DNA.
DNA:	Deoxyribonucleic acid.
dNTP:	Deoxynucleotide triphosphate.
E:	Envelope.
ELISA:	Enzyme linked immunosorbent assay.
HBV:	Hepatitis B virus.
HCC:	Hepatocellular carcinoma.
HCV:	Hepatitis C virus.
HDV:	Hepatitis delta virus.
HIV:	Human immunodeficiency virus.
IFN:	Interferon.
IVD:	Intravenous drug.
LCR:	Ligase chain reaction.
LMP:	Large multicatalytic protease.
Meq:	Million equivalent.
NCR:	Non coding region.
NS:	Non structural.
r-A:	Ribonucleic adenine.
RIBA:	Recombinant immunoblot assay.
RNA:	Ribonucleic acid.
RT-PCR:	Reverse transcription polymerase chain reaction.
r-U:	Ribonucleic uracil.
STATs:	Signal-transducing transcriptional activators.
TAP:	Transporter associated with antigen presentation.



---

## LIST OF FIGURES

### Figures of Review of Literature:

- Fig. (1):** .....(6)  
Organization of HCV genome.
- Fig. (2):** .....(33)  
HCV encoded antigens used for anti-HCV  
antibody detection in first (1), second (2)  
and third (3) generation antibody tests.
- Fig. (3):** .....(39)  
Principle of b.DNA assay.
- Fig. (4):** .....(41)  
Accurate HCV RNA quantification by b.DNA  
assay.
- Fig. (5):** .....(44)  
Ligase chain reaction.

### Figures of Results:

- Fig. (1):** .....(86)  
Frequency of the different HCV serotypes in  
the studied group of patients.
- Fig. (2):** .....(87)  
Response rate to interferon therapy in the  
studied patients with different HCV  
serotypes.

---

<b>Fig. (3):</b> .....	<b>(90)</b>
Mean values of HCV RNA titer in different HCV serotypes.	
<b>Fig. (4):</b> .....	<b>(94)</b>
Mean levels of ALT and AST in responders before and after treatment (n=11).	
<b>Fig. (5):</b> .....	<b>(95)</b>
Mean levels of ALT and AST in non-responders before and after treatment (n=40).	
<b>Fig. (6):</b> .....	<b>(100)</b>
Frequency of different forms of liver affection in biopsied patients (n=45).	
<b>Fig. (7):</b> .....	<b>(102)</b>
Pretreatment mean values of HCV RNA in different forms of liver affection.	
<b>Fig. (8):</b> .....	<b>(104)</b>
Results of PCR before and after treatment.	
<b>Fig. (9):</b> .....	<b>(109)</b>
Mean values of HCV RNA titer in both male and female patients.	

---

**List of Figures**

---

## LIST OF TABLES

Table (1): .....	(56)
Table (2): ..... Descriptive statistics of different parameters of all patients (n=51).	(70)
Table (3): ..... Statistical presentation of different parameters of all patients.	(79)
Table (4): ..... Descriptive statistics for responder group (R) (n=11).	(80)
Table (5): ..... Descriptive statistics for nonresponder group (NR) (n=40).	(81)
Table (6): ..... Detection of association between HCV serotyping and genotyping assays.	(84)
Table (7): ..... Frequency of HCV serotypes detected in the 51 patients.	(85)
Table (8): ..... Detection of the association between serotype and response to interferon-alpha treatment using the Chi-square test.	(85)

---

<b>Table (9):</b> .....	<b>(88)</b>
Detection of the association between serotype and histology of liver disease using the Chi-square test.	
<b>Table (10):</b> .....	<b>(89)</b>
Detection of association between serotype and HCV RNA quantitation (n=36).	
<b>Table (11):</b> .....	<b>(92)</b>
Comparison between ALT and AST before and after treatment in all patients group (n=51).	
<b>Table (12):</b> .....	<b>(93)</b>
Comparison between ALT and AST before and after treatment in responder group (R) (n=11, 21.6%).	
<b>Table (13):</b> .....	<b>(93)</b>
Comparison between ALT and AST before and after treatment in non responder group (NR) (n=40, 78.4%).	
<b>Table (14):</b> .....	<b>(96)</b>
Comparison between responder (R) and nonresponder (NR) groups regarding different parameter studied.	
<b>Table (15):</b> .....	<b>(97)</b>
Detection of association between HCV serotype and liver enzymes (ALT & AST).	

---

**List of Tables**

---